Publication | Closed Access

Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: A randomized, open-label, phase IIb, 5-year study in Indian patients

Indian PatientsOncologyNeoadjuvant Therapy5-Year StudyPathologyPhase IibHead And Neck CancerHead And Neck SurgeryCancer TreatmentNeck OncologyMedicineRadiation OncologyCancer Research